CHRS Stock Summary and Trading Ideas (Coherus Biosciences | NASDAQ:CHRS)

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Coherus Biosciences trades on the NASDAQ stock market under the symbol CHRS.

As of April 19, 2024, CHRS stock price climbed to $2.07 with 2,819,406 million shares trading.

CHRS has a beta of 2.22, meaning it tends to be more sensitive to market movements. CHRS has a correlation of 0.04 to the broad based SPY ETF.

CHRS has a market cap of $234.94 million. This is considered a Small Cap stock.

Last quarter Coherus Biosciences reported $92 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.50.

In the last 3 years, CHRS stock traded as high as $19.32 and as low as $1.43.

The top ETF exchange traded funds that CHRS belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.

CHRS has underperformed the market in the last year with a price return of -74.6% while the SPY ETF gained +21.2%. CHRS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.2% and -14.8%, respectively, while the SPY returned +3.0% and -4.5%, respectively.

CHRS support price is $1.91 and resistance is $2.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CHRS stock will trade within this expected range on the day.